In this article we examine the ways in which selective protein degradation provides an extra dimension to the regulation of such signalling cascades. We discuss (i) how both lysosomal and proteasomal systems are used to attenuate kinase and rho family GTPase signalling, thereby coupling activation with degradation, (ii) signal propagation contingent upon the selective degradation of inhibitory components, exemplified by the degradation of I kappa B to activate NF-kappa B signalling, and (iii)
tonic suppression of signalling pathways by turnover of the transcription factors beta-catenin and p53. (c) 2012 Elsevier Ltd. All rights reserved.”
“Objective Transcatheter arterial chemoembolization Microtubule Associat inhibitor (TACE) is an essential therapy for patients with hepatocellular carcinoma (HCC) in whom administering other treatments such as liver transplantation, resection or local therapy is not feasible. The purpose of our study was to determine the independent risk factors for one-year recurrence and two-year mortality in patients treated solely with TACE.\n\nMethods We conducted a retrospective cohort study of 34 consecutive patients (Group 1) with incident HCC who were treated solely with epirubicin-based TACE between April 2004 and March 2009. A subgroup
analysis was performed among 24 patients (Group 2) who underwent complete Apoptosis inhibitor TACE confirmed with abdominal computed tomography (CT) one month later. Tumor recurrence was evaluated using contrast CT every three months after the initial TACE. We calculated Kaplan-Meier estimates and performed a multiple regression analysis using a Cox-proportional hazard model.\n\nResults The patients in Group 1 (men, 59%), all of whom had liver cirrhosis, underwent TACE as the sole therapy for HCC. Kaplan-Meier estimates revealed a two-year survival rate [95% CI] of 70% [48-84%]. For the non-Child A patients, the adjusted hazard ratio (HR) [95% CI] for two-year survival was
7.1 [1.06-51.7]. In Group 2, the Kaplan-Meier estimate of the one-year recurrence rate [95% CI] was 61% [42-81%]. The adjusted HRs [95% CIs] for one-year recurrence for age and indocyanine Smoothened Agonist in vitro green (ICG) 15-min > 30% were 1.1 [1.0-1.26] and 7.87 [1.94-45.1], respectively.\n\nConclusion Non-Child A cirrhosis is an independent risk factor for two-year mortality in patients treated solely with TACE. For ICG 15-min > 30%, careful monitoring for HCC recurrence at one year, even after complete TACE, is warranted.”
“Purpose: This study aimed to establish the safety of outpatient I-131-rituximab radioimmunotherapy by measuring the radiation exposure of hospital staff, carers, and members of the public and by estimating the environmental impact of radioactive urinary excretion.